

Venue: Exhibition, Ground Level
Presentation: Tuesday 2 July, 12:30-14:30

The Poster Exhibition is open from Mon 1 - Wed 3 July from 10:00 to 18:30. Posters will be displayed for the duration of the conference.

Authors will stand by their posters between 12:30 and 14:30 on their assigned day of presentation to answer questions and provide further information on their study results.

Track A > Basic Sciences

PE220-223	Intrinsic cellular defences and restriction factors
<p> Early interferon block to HIV-1 transduction in macrophages despite degradation of the SAMHD1 restriction factor <i>L. Dragin, L. Anh Nguyen, H. Lahouassa, A. Sourisce, B.C. Ramirez, B. Kim, F. Margottin-Goquet</i> <i>France</i> </p>	
<p> A population-based matched-cohort study on insertion/deletion polymorphism of the APOBEC3B gene and risk of HIV-1 <i>M. Imahashi, T. Izumi, J. Imamura, K. Matsuoka, Y. Koyanagi, A. Takaori-Kondo, Y. Yokomaku, T. Naoe, W. Sugiura, Y. Iwatani</i> <i>Japan</i> </p>	
<p> Study of the infection profile of NRTI/NNRTI-resistant HIV-1 in monocytes and macrophages <i>D.N. Singhroy, T. Mesplede, H. Xu, M.A. Wainberg</i> <i>Canada</i> </p>	
<p> Mov10 and APOBEC3G localization to processing bodies (P Bodies) is not required for virion encapsidation and antiviral activity <i>T. Izumi, R. Burdick, W.-S. Hu, V. Pathak</i> <i>United States</i> </p>	
PE224-225	NK cells and dendritic cells
<p> Immune reconstitution and immune senescence of NK cells in HIV-1-infected patients after initiation of antiretroviral therapy <i>F. Ahmad, H. Hong, N. Bhatnagar, J. Eberhard, I.-N. Lu, B.A. Bollmann, M. Zielinska-Skowronek, R.E. Schmidt, D. Meyer-Olson</i> <i>Germany</i> </p>	
<p> Analysis of NK cell receptor-ligand expression in the prevention of AIDS-defining opportunistic infections in patients with low CD4+ T cell count <i>F. Bisio, F. Bozzano, E. Marras, C. Viscoli, A. Di Biagio, L. Moretta, A. De Maria</i> <i>Italy</i> </p>	
PE226-227	Monocytes and macrophages
<p> HIV-1 stimulates human monocytes to produce BAFF through type I IFN and its secretion level shows sex-related differences <i>A.M. Gomez, M. Ouellet, M. Tremblay</i> <i>Canada</i> </p>	
<p> The anti-apoptotic c-IAP-2 gene protects human monocytic cells against HIV-Vpr-mediated mitochondrial membrane depolarization and apoptosis: involvement of TRAF 1/2 via sequential inhibition of pro-apoptotic Caspase 8, Bid and Bax <i>M. Saxena, A. Busca, A. Kumar</i> <i>Canada</i> </p>	

PE228	Other innate immune responses
<p> Role of inflammatory cytokines and TLR ligands in modulating genital tract-derived dendritic cell activation <i>M.S. Shey, N.R. Maharaj, L.J. Liebenberg, D. Archary, S. Ngcapu, N. Samsunder, N. Garrett, Q. Abdool-Karim, S. Abdool-Karim, J.-A. Passmore</i> <i>South Africa</i> </p>	
PE229-231	Antibody diversity and function
<p> Antibody and T cell response to the protease cleavage sites drive extensive mutations and correlated with protection against higher dose of SIVmac239 challenge and disease progression in Cynomolgus macaques <i>M. Luo, D. Tang, C. Rupert, X.-Y. Yuan, J.C. Pinto, C. Prego, M. Alonso, C. Barry, R. Pilon, D. La, C. Daniuk, J. Tuff, S. Pillet, T. Bielawny, C. Czarniecki, P. Lacap, G. Wang, S. Tyler, B. Liang, T. Ball, P. Sandstrom, G. Kobinger, F. Plummer</i> <i>Canada</i> </p>	
<p> Generation and characterization of neutralizing anti-V3 scFvs against HIV-1 clade C <i>R. Kumar, R. Kumari, R. Andrabi, A. Tiwari, L. Khan, M. Makhdoomi, A. Nair, S. Kumar, N. Wig, S. Sinha, K. Luthra</i> <i>India</i> </p>	
<p> Protection against HIV transmission in HIV vaccine efficacy trials: immune correlates of risk and predictive value of non-human primate SIV and SHIV challenge studies <i>J.-L. Excler, S. Rerks-Ngarm, P. Pitisuttithum, S. Nitayaphan, J. Kaewkungwal, R.J. O'Connell, M.L. Robb, C. Andrews, V. Ngauy, N. Karasavvas, S.B. Zolla-Pazner, G.D. Tomaras, J. McElrath, P.B. Gilbert, B.F. Haynes, N. Michael, J.H. Kim</i> <i>United States</i> </p>	
PE232-234	B cells and alterations
<p> Antiretroviral therapy impacts on the quality of memory B-cell compartment in HIV-1 infection <i>S. Pensieroso, M. Ripa, S. Chiappetta, M. Pogliaghi, S. Nozza, G. Tambussi, G. Scarlatti</i> <i>Italy</i> </p>	
<p> Polyclonal patterns on serum protein electrophoresis correlate with lower CD4 counts in HIV-infected patients not on antiretroviral therapy <i>H. Ipp, A. Zemlin, S. Maleka, R. Erasmus, HAIG Study Group</i> <i>South Africa</i> </p>	
<p> Serum free light chains in patients with HIV not on antiretroviral therapy <i>A. Zemlin, H. Ipp, S. Maleka, M. Rensburg, R. Erasmus, HAIG Study Group</i> <i>South Africa</i> </p>	
PE235-237	CD4 T cell subsets
<p> Early but un-sustained restoration of Gag-Specific-CD4-T cells after antiretroviral therapy in subjects with advanced HIV-associated immunodeficiency <i>D.C. Hsu, S.J. Kerr, T. Iampornsin, S.L. Pett, A. Avihingsanon, P. Thongpaeng, S. Ubolyam, J. Ananworanich, A.D. Kelleher, D.A. Cooper</i> <i>Australia</i> </p>	

TUPE236 **Highly simplified CD4 analysis on a novel touch-screen-based cell analyzer**
J. Clor, P. de Borja, B. Goldman, K. Tran, R. Lefebvre, L. Rollins, J. Whalley, R. Pittaro, K. Tyagarajan
 United States

TUPE237 **Clinical, immunological and treatment-related predictors of normalisation of CD4/CD8 ratio: effect of naïve and memory T cell subsets**
W. Tinago, E. Coghlan, A. Macken, B. Doaks, J. Mc Andrew, J. Lambert, G. Sheehan, P.W.G. Mallon, on behalf of the Mater Immunology Study Group
 Ireland

PE238-240 Cellular immunity

TUPE238 **HIV-1 Env-specific conformational ADCC epitopes: potential utility for HIV vaccine design**
V. Madhavi, M. Kramski, L. Wren, R. Center, S. Kent, I. Stratov
 Australia

TUPE239 **Antibody-opsonization reduces the power of dendritic cells to activate HIV-specific T_H1s**
W. Posch, S. Cardinaud, C. Hamimi, M.P. Dierich, G. Pancino, C. Lass-Flörl, A. Moris, A. Saez-Cirion, D. Wilflingseder
 Austria

TUPE240 **Complement as an endogenous enhancer for dendritic cell-mediated induction of HIV-specific CTLs**
W. Posch, A. Moris, M.P. Dierich, C. Lass-Flörl, D. Wilflingseder
 Austria

PE241-242 Mucosal immunity

TUPE241 **A living mucosal immune system screen for antigen optimization**
J. Wu, S.-H. Huang, N. Hand, C. Cappiello, S. Zeichner
 United States

TUPE242 **Severe depletion and exhaustion of mucosal-associated invariant T (MAIT) cells in HIV-1-infected patients**
J. van Lunzen, P. Hartjen, D. Ebert, I. Toth, C. Beisel, J. Schulze zur Wiesch
 Germany

PE244 Host genetics of susceptibility and resistance

TUPE244 **The DC-SIGNR 7/5 genotype is associated with high dendritic cell counts and their subsets in patients infected with HIV-1**
O. Chaudhary, M. Bala, J. Singh, A. Hazarika, R. Kumar, K. Luthra
 India

PE245 Highly exposed seronegative individuals (HESN)

TUPE245 **Polymorphisms in the IRF1 gene associated with reduced HIV susceptibility and their impact on plasma and cervical lavage cytokine/chemokine expression**
A. Sivro, R.-C. Su, J. Lajoie, J. Kimani, W. Jaoko, K. Fowke, F.A. Plummer, T.B. Ball
 Canada

PE246-247 Correlates of protection

TUPE246 **Functional cure after long term HAART initiated during early HIV infection: a comprehensive case study**
J. van Lunzen, J. Schulze zur Wiesch, U. Schuhmacher, I. Hauber, J. Hauber
 Germany

TUPE247 **Higher Gag-specific but lower Env-specific CD8+ T cell responses in SIV controllers**
H. Ishii, N. Takahashi, S. Matsuoka, T. Matano
 Japan

Track B > Clinical Sciences

PE248-251 Staging, progression of disease: impact of co-factors / viral clade / tropism / genetic factors/ gender/age/ coinfection

TUPE248 **Lower immunologic response to cART in HIV-infected migrants from Sub-Saharan Africa compared to non-migrants in France: the ANRS-COPANA cohort**
R. Dray-Spira, N. Billaudeau, R. Seng, M. Ghislain, D. Salmon-Ceron, G. Pialoux, L. Cotte, L. Camille, L. Meyer
 France

TUPE249 **Host genetic factors associated with symptomatic primary acute HIV infection and disease progression among Argentinean seroconverters**
R.S. Coloccini, Y. Ghiglione, G. Turk, N. Laufer, M.E. Socias, O. Sued, P. Cahn, H. Salomón, A. Mangano, M.A. Pando, Grupo Argentino de Seroconversión
 Argentina

TUPE250 **Increased risk of AIDS development and AIDS-related death in seroconverted individuals infected with HIV-1 recombinant form A3/CRF02_AG compared to individuals infected with sub-subtype A3**
A. Palm, J. Esbjörnsson, F. Månsson, A. Kvist, P.-E. Isberg, M. Jansson, H. Norrgren, P. Medstrand
 Sweden

TUPE251 **Effect of helicobacter pylori infection on the outcome of first-line antiretroviral therapy in Cameroon**
T. Feldt, G. Burchard, S. Schmiedel, J. Jochum, J.F. Drexler, C.N. Awosom, N. Taka, G. Tayong, J. van Lunzen, A. Zoufaly
 Germany

PE252 Acute and early infection

TUPE252 **A novel acute retroviral syndrome severity score predicts surrogate markers associated with HIV-1 disease progression**
D.L. Braun, R. Kouyos, C. Grube, B. Joos, H. Kuster, B. Ledergerber, H. Günthard, Zurich Primary HIV Infection Study Group
 Switzerland

PE253-260 HIV disease burden: morbidity/mortality/ impact on life expectancy

TUPE253 **Incidence and impacts of antiretroviral therapy on malignant cervical neoplasm among HIV-infected women in Taiwan 2000-2008**
Y.-C. Chen
 Taiwan, Province of China

TUPE254 **Impact of varying CD4 count levels on the prognostic value of baseline and last haemoglobin measurement on death among patients on antiretroviral therapy**
S. Takuva, M. Maskew, D. Evans, I. Sanne, P.A. Macphail, M.P. Fox
 South Africa

TUPE255	<p>Mortality in the combination antiretroviral therapy era: will switching to another treatment centre become a risk factor?</p> <p><i>G. Sturm, R. Zangerle, for the AHIVCOS Group Austria</i></p>	TUPE265	<p>Development of the BD FACSPresto? instrument, a new point-of-care system for CD4+ counting</p> <p><i>S. Bornheimer, N. Bui, D. Le, H. Wai, A. Tran, E. Goldberg, P. Bouic, W. Huang, J. Sugarman, M. Crowe, V. Kumar, J. Shook, C. Tomas, J. Yu, A. Clark, E. Broszeit, R. Chen, C. Bush-Donovan</i> <i>United States</i></p>
TUPE256	<p>Considerable gaps in life expectancy among HIV-positive individuals initiating HAART in British Columbia, Canada</p> <p><i>R.S. Hogg, K. Chan, A. Cescon, H. Samji, B. Yip, G. Colley, V.D. Lima, J.S.G. Montaner</i> <i>Canada</i></p>	TUPE266	<p>The CD4/CD8 ratio identifies treated HIV-infected subjects at increased risk of cardiovascular events and non-AIDS neoplasias</p> <p><i>S. Serrano-Villar, M.J. Pérez-Ellás, F. Dronza, J.L. Casado, A. Moreno, E. Navas, J.M. Hermida, C. Quereda, J.A. Pérez-Molina, S. Moreno</i> <i>Spain</i></p>
TUPE257	<p>Late HIV diagnosis, late initiation of combination ART and mortality in Europe: variation by educational level</p> <p><i>S. Lodi, COHERE in EuroCoord</i> <i>Spain</i></p>	TUPE267	<p>Plasma HIV-2 RNA according to CD4 count strata among untreated HIV-2-infected adults in Côte d'Ivoire: the IeDEA West Africa collaboration</p> <p><i>D.K. Ekouevi, X. Anglaret, P.A. Coffie, S.P. Eholie, V. Avettand-Fénoël, E. Messou, A. Minga, J.C. Plantier, F. Damond, F. Dabis, C. Rouzioux, IeDEA West Africa Collaboration</i> <i>Ivory Coast</i></p>
TUPE258	<p>The free and universal access to antiretroviral therapy does not always decrease mortality: the case of Mexico</p> <p><i>E. Bravo-Garcia, H. Ortiz-Perez</i> <i>Mexico</i></p>	TUPE268	<p>Implementing selective viral load testing algorithm in management of patients on ART in an urban setting in Kenya: the impact of repeat viral load testing</p> <p><i>L. Nyabiage, C. Mwachari, B. Ouma, P. Nziwa, J. Nzai, P. Muange, G. Oyugi, G. Onyango, V. Makokha, F. Odhiambo, C. Kimani, B. Onyuka, S. Ojoo, A. Amoroso, R. Ngethe, S. Ochola, R. Redfield</i> <i>Kenya</i></p>
TUPE259	<p>Socio-behavioural determinants of mortality in HIV-infected patients receiving combined antiretroviral treatment (cART): results from the ANRS CO8 APROCO-COPILOTE cohort</p> <p><i>C. Protopopescu, M.P. Carrieri, V. Le Moing, P. Reboud, L. Piroth, L. Cuzin, F. Couturier, F. Raffi, B. Spire, C. Lepout, the ANRS CO 8 APROCO-COPILOTE Study Group</i> <i>France</i></p>	TUPE269	<p>Predicting treatment failure (TF) in adults and children on antiretroviral therapy (ART): systematic review of the performance characteristics of the 2010 World Health Organization (WHO) criteria for virologic failure</p> <p><i>G.W. Rutherford, A.T. Anglemyer, P. Easterbrook, T. Horvath, M. Vitoria, M. Penazzato, M. Doherty</i> <i>United States</i></p>
TUPE260	<p>Increases in life expectancy among treated HIV-positive individuals in the United States and Canada, 2000-2007</p> <p><i>R.S. Hogg, K.N. Althoff, H. Samji, A. Cescon, S. Modur, K. Buchacz, A.N. Burchell, M. Cohen, K.A. Gebo, M.J. Gill, A. Justice, G. Kirk, M.B. Klein, P.T. Korthuis, J. Martin, S. Napravnik, S.B. Rourke, T.R. Sterling, M.J. Silverberg, S. Deeks, L.P. Jacobson, R.J. Bosch, M.M. Kitahata, J.J. Goedert, R. Moore, S.J. Gange, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) of IeDEA</i> <i>United States</i></p>		
PE261-269	New monitoring strategies including rapid and point of care tests		
TUPE261	<p>Simplification of a validated clinical prediction score to detect virological failure on first-line antiretroviral treatment in Cambodia</p> <p><i>J. van Griensven, V. Phan, T. Sopheak, O. Koole, J. Menten, L. Lynen, B. Chim</i> <i>Cambodia</i></p>	PE270-279	Viral resistance testing in clinical trials and practice
TUPE262	<p>Comparative evaluation of Plasma Preparation Tube (PPT) and EDTA samples using Roche's Cobas TaqMan HIV-1 and Abbott's RealTime HIV-1 v. 4.00 assays</p> <p><i>D. Adachi, M. Benedet, J.W.-T. Tang, G. Cloherty</i> <i>United States</i></p>	TUPE270	<p>Prevalence of transmitted antiretroviral drug resistance in treatment-naïve HIV-infected individuals in southern Taiwan, 2007-2011</p> <p><i>L.T. Chen, P.Y. Chou, Y.H. Chen, T.Y. Hsu, H.C. Tsai, Y.S. Chen</i> <i>Taiwan, Province of China</i></p>
TUPE263	<p>Detection of cryptococcal antigenaemia from whole blood specimens for rapid diagnosis of cryptococcal disease among HIV-infected adults in South Africa</p> <p><i>N.P. Govender, T.G. Zulu, D. Lawrie, N. Bosman, T. Nana, N. Govender, S. Lindani, V.C. Quan, L. Coetzee, W. Stevens</i> <i>South Africa</i></p>	TUPE271	<p>Rilpivirine resistance mutations in HIV-infected pregnant women</p> <p><i>D.M. Cecchini, I. Zapiola, S. Fernandez Giuliano, M. Martinez, C. Rodriguez, M.B. Bouzas</i> <i>Argentina</i></p>
TUPE264	<p>Reliability of rapid blood test for the diagnosis of non-B subtypes and recombinant variants of HIV-1</p> <p><i>J. Goupil de Bouille, L. Hocqueloux, A. Guigon, G. Le Moal, D. Plainchamp, A. Theillay, A. Languille, T. Prazuck</i> <i>France</i></p>	TUPE272	<p>Impact of the HIV integrase genetic context on the phenotypic expression and <i>in vivo</i> dynamics of integrase inhibitor resistance mutations</p> <p><i>C. Delaugerre, N. Nguyen, F. Clavel, F. Mammano</i> <i>France</i></p>
		TUPE273	<p>Routine next generation sequencing of HIV-1 RT in the University Hospital of Bordeaux, France: first results and perspectives</p> <p><i>P. Pinson, P. Bellocave, M. Vandenhende, J. Papuchon, B. Tauzin, H. Fleury</i> <i>France</i></p>

<p> TUPE274 Transmitted drug resistance in HIV-2-infected antiretroviral-naïve patients from the French HIV-2 cohort ANRS CO05 <i>C. Charpentier, B. Visseaux, A. Bénard, G. Peytavin, F. Damond, C. Roy, A. Taieb, G. Chêne, S. Matheron, F. Brun-Vézinet, D. Descamps, French HIV-2 Cohort ANRS CO05 France</i> </p>	<p> TUPE282 Once-daily dolutegravir (DTG; S/GSK1349572) has a renal safety profile comparable to raltegravir (RAL) and efavirenz in antiretroviral (ART)-naïve adults: 48 week results from SPRING-2 (ING113086) and SINGLE (ING114467) <i>L.D. Curtis, S. Min, G. Nichols, B. Wynne, C. Stainsby, A. Aylott, S. Piscitelli, J. Goodrich, SPRING-2 and SINGLE Teams United Kingdom</i> </p>
<p> TUPE275 Transmitted HIV-1 antiretroviral resistance in pregnant women from Rio de Janeiro, Brazil <i>J.C. Couto-Fernandez, G. Ravasi, I. Alonso, A. Navarini, A. Tanuri, M. Morgado, J.H. Pilotto, Drug-naïve HIV-1 infected pregnant woman Brazil</i> </p>	<p> TUPE283 Safety and tolerability of switching from twice daily raltegravir plus truvada to STRIBILD in virologically suppressed, HIV-1-infected subjects at week 24 <i>G. Crofoot, R. Ortiz, A. Mills, B. Rashbaum, W. Towner, D. Ward, C. Brinson, H. Cao, J. Szwarcberg United States</i> </p>
<p> TUPE276 Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay <i>L. Gu, Y. Han, Y. Hung, N. Hosoya, T. Zhu, J. Gohda, Q. Cui, A. Iwamoto, T. Li, T. Ishida Japan</i> </p>	<p> TUPE284 STaR study: single tablet regimen rilpivirine/emtricitabine/tenofovir DF has non-inferior efficacy compared to efavirenz/emtricitabine/tenofovir DF and improves patient reported outcomes <i>C. Cohen United States</i> </p>
<p> TUPE277 Cross-sectional and prospective cohort surveys provide comparable findings in surveillance of virological outcome and emergence of HIV drug resistance among Vietnamese adults receiving first-line antiretroviral therapy <i>H.H.K. Thu, P.D. Quang, L.O. Anh, K.V. Nghia, N.V. Trung, D.T. Nhan, T.T.X. Lien Vietnam</i> </p>	<hr/> <p> PE285-289 Acute and early infection including management of patients with acquired viral resistance </p>
<p> TUPE278 World Health Organization HIV drug resistance surveillance in children less than 18 months newly diagnosed with HIV in Zimbabwe <i>C.C. Chakanyuka-Musanhu, M. Penazzato, T. Apollo, J. Dzangare, S. Mtapuri-Zinyowera, O. Mugurungi, E. Martin, M. Jordan, J. Perriens, S. Bertagnolio Zimbabwe</i> </p>	<p> TUPE285 Molecular diversity of HIV-1 and surveillance of transmitted drug resistance variants in treatment naïve patients in Kuala Lumpur, Malaysia: 5 years after active rollout of HAART <i>L.Y. Ong, S.N.H. Razak, Y.M. Lee, S. Sri La Sri Ponnampalavanar, S.F. Syed Omar, R.I. Azwa, K.K. Tee, A. Kamarulzaman Malaysia</i> </p>
<p> TUPE279 Prevalence and patterns of genotypic resistance mutations among children failing first- and second-line highly active antiretroviral therapies (ART) at the Botswana-Baylor Children's Clinical Centre of Excellence (COE) <i>D. Joel, P. Rowinsky, M. Marape, M. Matshaba, A. Sathyamoorthi, B. Kirk, T. Marukutira, V. Mabikwa, G. Anabwani Botswana</i> </p>	<p> TUPE286 Characteristics and outcomes of adult patients who receive HIV care before the start of antiretroviral therapy in Sub-Saharan Africa <i>M. Bastard, N. Nicolay, S. Balkan, E. Szumilin, E. Poulet, M. Pujades-Rodriguez France</i> </p>
<p> PE280-284 Clinical trials - phase III/post-licensing </p>	<p> TUPE287 Role of cumulative HIV viremia on long term CD4 count after treatment initiation during primary infection <i>R. Seng, C. Goujard, C. Rouzioux, L. Meyer France</i> </p>
<p> TUPE280 Renal safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF (STB) and cobicistat-boosted protease inhibitor regimens in HIV-1-infected patients with mild to moderate renal impairment <i>F. Post, J. Andrade Villanueva, M. Fisher, Y. Liu, L. Zhong, A. Cheng, M. Rhee, J. Szwarcberg United Kingdom</i> </p>	<p> TUPE288 Burden of NNRTI resistance in treatment-naïve HIV-1-infected patients: a systematic review and meta-analysis <i>S.J. Snedecor, L. Sudharshan, K. Nedrow, A. Bhanegaonkar, K.N. Simpson, S. Haider, R. Chambers, M. Tawadrous, C. Craig, J. Stephens United States</i> </p>
<p> TUPE281 Subgroup analyses of 96-week efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF <i>D. Cooper, A. Zolopa, J. Rockstroh, C. Orkin, H.J. Stellbrink, S. Walmsley, L. Zhong, M. Fordyce, M. Rhee, J. Szwarcberg Australia</i> </p>	<p> TUPE289 Comparison of patient characteristics and trends of transmitted drug resistant HIV between recent and long-term infection among treatment-naïve HIV-1-infected populations in Japan <i>J. Hattori, H. Gatanaga, M. Kondo, K. Sadamasu, S. Kato, H. Mori, R. Minami, K. Uchida, Y. Yokomaku, W. Sugiura, Japanese Drug Resistance HIV-1 Surveillance Network Japan</i> </p>
	<hr/> <p> PE290-299 Adherence </p>

<p> TUPE290 Non-adherence to first-line cART in HIV-infected patients in Asia: TASER-M analysis <i>A. Jiamsakul, N. Kumarasamy, R. Ditangco, P. Li, P. Phanuphak, T. Sirisanthana, S. Sungkanuparph, P. Kantipong, C. Lee, M. Mustafa, T. Merati, A. Kamarulzaman, T. Singtoroj, M. Law</i> <i>Australia</i> </p>	<p> TUPE299 Mobile health technologies (mHealth) for promoting adherence to antiretroviral therapy: a systematic review <i>L. Butler, T. Horvath, R. Baggaley, A. Suthar, E. Negussie</i> <i>Switzerland</i> </p>
<p> TUPE291 Clinical and immunological outcomes according to adherence to HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa <i>E. Focà, S. Odolini, S. Calza, V. Pietra, A. Noris, P. Ouedraogo, G. Sulis, J. Simpole, S. Pignatelli, F. Castelli</i> <i>Italy</i> </p>	<p> PE300-302 When to start therapy </p>
<p> TUPE292 Factors associated with achieving undetectable HIV-1 RNA level for HIV-infected patients on antiretroviral therapy in a clinical cohort from Rio de Janeiro, 1997-2011 <i>D.A. Martin, P.M. Luz, V.G. Veloso, R.I. Moreira, S.W. Cardoso, J.E. Lake, J.L. Clark, J.D. Klausner, B. Grinsztejn</i> <i>Brazil</i> </p>	<p> TUPE300 Timing of combination antiretroviral therapy initiation in Canada, 2000-2010 <i>A. Cescon, K. Chan, M.R. Loutfy, S.R. Hosein, A.N. Burchell, C. Cooper, M.B. Klein, N. Machouf, J.M. Raboud, A. Rachlis, S.B. Rourke, C. Tsoukas, J.S.G. Montaner, R.S. Hogg, CANOC Collaboration</i> <i>Canada</i> </p>
<p> TUPE293 Elvitegravir/cobicistat/emtricitabine/tenofovir DF demonstrates comparable efficacy to efavirenz/emtricitabine/tenofovir DF in subjects with adherence < 95% <i>P. Shalit, C. Cohen, A. Mills, F. Bredeek, G. Crofoot, T. Nguyen, L. Dau, M. Rhee, D. Piontkowsky, J. Szwarcberg</i> <i>United States</i> </p>	<p> TUPE301 The effects of the new WHO recommendations regarding eligibility for ART on the number eligible for treatment in low- and middle-income countries (LMIC) <i>J. Stover, M. Doherty, M. Vitoria, P. Easterbrook, J. Perriens, P. Ghys</i> <i>Switzerland</i> </p>
<p> TUPE294 Adherence and HIV drug resistance: how adherence behaviours can explain early and late resistances to NNRTI regimens in the Stratall ANRS 12110/ESTHER trial in Cameroon <i>M. Meresse, L. March, C. Kouanfack, C.-R. Bonono, S. Boyer, G. Laborde-Balen, A.F. Aghokeng, M. Suzan-Monti, E. Delaporte, B. Spire, C. Laurent, M.P. Carrieri, Stratall ANRS 12110 / ESTHER Study Group</i> <i>France</i> </p>	<p> TUPE302 Early initiation of antiretroviral therapy (ART) for individuals with HIV infection: a systematic review <i>A. Anglemyer, G. Rutherford, P. Easterbrook, T. Horvath, M. Vitoria, M. Doherty</i> <i>United States</i> </p>
<p> TUPE295 Adherence to antiretroviral therapy during pregnancy and the first year postpartum among women in Ukraine <i>H. Bailey, C. Townsend, I. Semenenko, R. Malyuta, M. Cortina-Borja, C. Thorne, for the Ukraine European Collaborative Study</i> <i>United Kingdom</i> </p>	<p> PE303-305 Switch strategies </p>
<p> TUPE296 Community ART delivery model for high retention of patients on antiretroviral therapy: The AIDS Support Organisation (TASO) operational research findings east and central Uganda, resource-limited setting <i>J. Wamboga Magawa, D. Mpiima</i> <i>Uganda</i> </p>	<p> TUPE303 Rates and factors associated with major modifications to first-line combination antiretroviral therapy: results from the Asia-Pacific region <i>S.T. Wright, M.A. Boyd, E. Yuniastuti, M.G. Law, T. Sirisanthana, J. Hoy, S. Pujari, M.P. Lee, K. Petoumenos, on behalf of the Asia-Pacific HIV Observational Database (APHOD)</i> <i>Australia</i> </p>
<p> TUPE297 Treatment adherence and the efficacy of information, motivation and behavioural intervention on treatment adherence among people living with HIV/AIDS in Ibadan, Nigeria <i>O. Atibioko, I. Olusola, H. Osinowo</i> <i>Nigeria</i> </p>	<p> TUPE304 The choice of first-line regimen influences the likelihood of therapy switches and disease progression <i>V.D. Lima, Y. Chen, T. Kozai, R. Hogg, J. Montaner</i> <i>Canada</i> </p>
<p> TUPE298 Community-based approaches improve adherence to treatment and retention to care: a systematic review <i>L. Butler, T. Horvath, G. Kennedy, J. Chan, J. Rajan, A. Spaulding, R. Baggaley, J. Ferguson</i> <i>Switzerland</i> </p>	<p> TUPE305 Resistance analysis at week 48 in virologically-suppressed subjects switching to RPV/FTC/TDF single-tablet regimen (studies GS-US-264-0106 and GS-US-264-0111) <i>S.K. Chuck, D.P. Porter, R. Kulkarni, T. Fralich, M.D. Miller, K.L. White</i> <i>United States</i> </p>
	<p> PE306-307 Clinical trials and antiretroviral therapy for children </p>
	<p> TUPE306 Prevalence and impact of transmitted drug resistance (TDR) on response to ART in children <i>L. Wittkop, N. Ngo-Giang-Huong, EuroCoord-CHAIN-EPPICC Project Team</i> <i>Thailand</i> </p>
	<p> TUPE307 Failure in HIV-1-infected children on second-line antiretroviral treatment in Thailand <i>R. Suaysod, N. Ngo-Giang-Huong, S. Chalermpanmetagul, T. Cressey, S. Piyaworawong, S. Hanpinitak, S. Potchalongsin, S. Krikajornkitti, S. Na-Rajsima, P. Traisathit, G. Jourdain</i> <i>Thailand</i> </p>
	<p> PE308-314 Cohort studies of HIV- and ARV-related issues in children </p>

TUPE308 Incidence and associated factors of pulmonary tuberculosis in HIV-infected children after HAART in China: a retrospective study
W. Mu, Y. Zhao, X. Sun, X. Liu, F. Zhang
 China

TUPE309 Outcomes of HIV-infected children less than 2 years of age presenting to public HIV clinics in Kenya 2004-2010: a national retrospective cohort study
B. Ng'eno, L. Nganga, S. Modi, A. Gichangi, A. Waruru, A. Katana, I. Mukui, J. Wamicwe, I. Inwani
 Kenya

TUPE310 Virological treatment failure in children in a decentralized HIV programme in rural South Africa: association with household and maternal factors
J. Ndirangu, C. Thorne, M.-L. Newell
 South Africa

TUPE311 Higher rates of triple class virologic failure in perinatally HIV-infected teenagers compared to heterosexually infected young adults in the PLATO II study
D.M. Gibb, on behalf of the PLATO II Project Team of COHERE
 United Kingdom

TUPE312 Treatment outcomes in HIV-infected children in Kenya, 2004-2011: results from a national retrospective cohort study
I. Mukui, A. Katana, I. Inwani, B. Ng'eno, E. Ngugi, A. Gichangi, A. Waruru, A. Mwangi, J. Wamicwe, M. Kimani, S. Modi, L. Nganga
 Kenya

TUPE313 When to start ART in children aged 2-5 years? Causal modeling analysis of IeDEA southern Africa
M.-A. Davies, M. Schomaker, T. Gsponer, J. Ndirangu, S. Phiri, H. Moultrie, K. Technau, V. Cox, J. Giddy, C. Chimbetete, R. Wood, C. Bolton-Moore, H. Rabie, B. Eley, L. Mussa Muhe, M. Penazzato, S. Essajee, O. Keiser, M. Egger, IeDEA Southern Africa Collaboration
 South Africa

TUPE314 Long-term immune response in HIV-infected children receiving highly active antiretroviral therapy in Thailand: outcomes at 7-years
I.J. Collins, N. Ngo-Giang-Huong, G. Jourdain, C. Chanta, A. Puangsombat, R. Kwanchaipanich, S. Bunjongpak, T. Cressey, S. Le Coeur, S. Jaffar, M. Lallemand, PHPT Study Group
 United Kingdom

Track C > Prevention Science

PE315-318 Optimising multicomponent interventions for different epidemic settings and populations at risk

TUPE315 Integrated approach to HIV prevention intervention among the general population in Ogun State, Nigeria
D. Obinna, J. Muyiwa-Afolabi, T. Fadiya, O. Fatungase, A. Akinpelu
 Nigeria

TUPE316 STIs and risk behaviours for HIV transmission among people living with HIV in selected high HIV prevalence states in India: need for combination prevention approach for HIV control
T. Bhatnagar, K. Boopathi, R. Paranjape, S. Mehendale
 India

TUPE317 Changing HIV-related community norms: results from in-depth interviews with a longitudinal cohort of community members in NIMH Project Accept (HPTN 043)
H. van Rooyen, S. Maman, P. Stankard, O. Murima, T. Muravha, J. Ntrogwisangu, Z. Phakathi, N. Srirak, S.F. Morin, Project Accept (HPTN 043) Study Team
 South Africa

TUPE318 Optimizing multicomponent interventions for men who have sex with men (MSM) in Cameroon: factors associated with HIV testing
J.N. Park, E. Papworth, L. Moukam, I.B. Macauley, S. Billong, Y.R. Yomb, N. Nkoume, J. Eloundou, M. Lebreton, S. Ketende, A. Grosso, J.A. Lee, S. Baral
 United States

PE319 Design of combination prevention interventions

TUPE319 Evaluation of a HIV risk score within an outpatient sexual health clinic
C. Jones, K. Kuldaneck, P. Vickerman, A. Smith, J. Fox, L. Platt, S. Fidler
 United Kingdom

PE320-326 Increasing access and coverage of interventions

TUPE320 HIV risk perception and attitude towards voluntary counseling and testing (VCT) among female partners of injecting drug users (IDUs) in Kelantan, Malaysia
A. Mohd Nasarruddin, W.M. Zahiruddin, N.H. Nik Hussain, S.H. Ali, H. Mat Zubir
 Malaysia

TUPE321 Study on effectiveness of extension clinics of methadone maintenance treatment of Dehong prefecture, Yunnan province, China
Z. Guang, S. Jiangping, L. Hui, X. Hui, Dehong CDC Study Group
 China

TUPE323 Good program coverage in high HIV prevalence settings in western Kenya: preliminary results of the Nhdiwa HIV impact in population study
D. Maman, I. Mukui, B. Kirubi, B. Riche, C. Zeh, S. Masson, S. Elisabeth, E. Jean-Francois
 France

TUPE324 A mixed-method research on access to ART for people living with HIV in Nepal
A. Shrestha, A. Aryal, K.P. Bista
 Nepal

TUPE325 Factors associated with CD4 count testing service seeking by people living with HIV in far-western Nepal
A. Shrestha, A. Aryal, K.P. Bista
 Nepal

TUPE326 Stigma, personal attitude and type of ART service system (ARTSS): potential barriers toward the access to HIV/AIDS treatment under universal coverage (UC) in Thailand
S. Kongsin, S. Jiamton, K. Prom-On, S. Rongsumlee
 Thailand

PE327-329 Cost-effectiveness and interventions

TUPE327 Using cost-effectiveness analysis for interventions among youths to zero new infections
S. Kongsin, S. Jiamton, S. Rongsumlee, N. Boonruang, K. Prom-On, B. Youngvises, K. Tachapetpaiboon, S. Boonyai, K.M. Soe
 Thailand

<p> TUPE328 Global Fund support for FLHE implementation in Nigeria: innovation for achieving much with little <i>A. Oladeji, E. Uzegbunam, O. Atibioko, M. Olokodana, K. Osinowo, O. Ladipo, O. Ojomo, A. Hassan, B. Offiah, K. Nnorom, B. Ehimatie Nigeria</i> </p>	<p> TUPE338 The cascade of care: a promising tool in HIV surveillance <i>V.D. Lima, B. Nosyk, G. Colley, K. Heath, B. Yip, H. Samiji, R. Hogg, J. Montaner, on behalf of the STOP HIV/AIDS Study Group Canada</i> </p>
<p> TUPE329 Estimating dynamics of direct medical costs among individuals with HIV/AIDS <i>B. Nosyk, V. Lima, G. Colley, B. Yip, K. Heath, R. Hogg, J. Montaner, STOP HIV/AIDS Study Group Canada</i> </p>	<p> TUPE339 Prevalence of hepatitis B virus (HBV) and hepatitis C virus (HCV) infection among HIV-infected people who inject drugs in Zanzibar, Tanzania 2012 <i>A. Khatib, E. Matiko, S. Welty, F. Khatib, M. Dahoma, A. Khamis, A. Othman, M. Kibona, E. Kim, G. Rutherford Tanzania, United Republic of</i> </p>
<p> PE330 Economic-based HIV interventions (i.e., micro-capital/cash transfer/contingency management/housing/poverty reduction programmes) </p>	<p> TUPE340 Measuring the efficacy of the 'Mobility Exacerbated HIV Prevention and Impact Mitigation' program in Armenia: a quasi-experimental approach <i>E. Bakhshinyan, H. Madoyan, N. Bezelieva Ukraine</i> </p>
<p> TUPE330 Economic strengthening for female household heads: an integrated approach to improving OVC care and well-being in Nigeria <i>S. Mkeryi Amahson, Z. Kpamor, O. Doherty, O. Onoh, U. Adaji, G. Ojiakor, E. Bunde, C. Okoye, S. Steven, O. Onifade Nigeria</i> </p>	<p> TUPE341 Is the HIV epidemic stable in Latinoamerica? HIV prevalence and risk behaviour from a nationally representative survey among men who have sex with men in 24 metropolitan areas in Mexico <i>A. Colchero, S. Bautista-Arredondo, S. Sosa-Rubi, M. Romero-Martinez, C. Conde Mexico</i> </p>
<p> PE331-335 Gender sensitization, empowerment and violence reduction </p>	<p> TUPE342 Deconstructing the impact of behaviour change programming that uses messaging about the risk associated with multiple partnerships: results from a representative survey from Zimbabwe <i>R. Buzdugan, C. Benedikt, O. Mundaya, O. Mugurungi, C. Watadzaushe, J. Dirawo, B.O. Tambashe, G. Woelk, F.M. Cowan United States</i> </p>
<p> TUPE331 An analysis of HIV and gender-based violence (GBV) co-existence among HIV-positive: a TASO experience <i>B. Kizito Joseph Uganda</i> </p>	<p> TUPE343 HIV impact among injecting drug user using respondent-driven sampling in Malaysia: are we doing enough? <i>A. Suleiman, S. Ngadiman, F. Yuswan, A. Ayob, N. Ujang, M.A. Kamaluddin, T. Yik Koon, N. Hamdi Malaysia</i> </p>
<p> TUPE332 Gender inequality and HIV transmission <i>E. Richardson, A. Zolopa United States</i> </p>	<p> TUPE344 ART treatment eligibility and service uptake among a population-based rural cohort in Rakai, Uganda <i>R.M. Galiwango, R. Musoke, R. Ssekubugu, M. Nakafeero, J. Namuteete, G. Kigozi, F. Nalugoda, G. Nakigozi, F. Makumbi, G. Aluma, R.H. Gray, S.J. Reynolds, M.J. Wawer, D. Serwadda Uganda</i> </p>
<p> TUPE333 Actor-partner effects associated with experiencing intimate partner violence or coercion among male couples enrolled in an HIV prevention trial <i>K. Wall, P. Sullivan, D. Kleinbaum, R. Stephenson United States</i> </p>	<p> TUPE345 Impact of methadone maintenance on health utility, health care utilization and expenditure in drug users with HIV/AIDS <i>B. Tran, V. Nong Vietnam</i> </p>
<p> TUPE334 Mixed methods development of a screening tool for gender-based violence among internally displaced populations: use and implications for improving access to GBV services and HIV testing and care in Colombia <i>A. Wirtz, K. Pham, G. Jaquet, S. Loochkhart, T. Kidane, D. Cuspoca, N. Glass, L. Rubenstein United States</i> </p>	<p> TUPE346 Marriage and the risk of HIV infection in Rakai, Uganda <i>E. Naluqoda, D. Guwatudde, J. Bwanika, F. Wabwire-Mangen, F. Makumbi, T. Lutalo, J. Kagaayi, N. Sewankambo, G. Kigozi, D. Serwadda, X. Kong, M. Wawer, R. Gray Uganda</i> </p>
<p> TUPE335 Coffee talk: piloting a culturally appropriate behavioural intervention to decrease intimate partner violence and HIV in rural Ethiopia <i>V. Sharma, N. Deyessa United States</i> </p>	<p> PE347 Novel strategies for measuring incidence rates </p>
<p> PE336-337 Collectivization, mobilization, stigma reduction programmes </p>	<p> TUPE347 Identifying HIV transmission risk factors in men who have sex with men using molecular data <i>E. Volz, E. Mokotoff, M.-G. Brandt, S. Frost United States</i> </p>
<p> TUPE336 Measurement of the attitude of public health workers in Cross River State, Nigeria, towards people living with HIV/AIDS using the AIDS Attitude Scale <i>A. Etokidem, W. Ndifon, E. Nsan Nigeria</i> </p>	<p> PE348-352 Second and third generation surveillance strategies </p>
<p> TUPE337 Exploring levels of HIV-related knowledge and stigma among medical students <i>J. Audimulam, E. Jahncke, S. Archuleta Singapore</i> </p>	
<p> PE338-346 Measuring impact of prevention interventions at a population level </p>	

TUPE348	<p>Trends and patterns of HIV prevalence and risk behaviours among MSM captured in three consecutive community-based surveys in Hong Kong</p> <p><i>H.T.H. Wong, S.S. Lee, K.H. Wong, K.C.K. Lee</i> Hong Kong</p>	TUPE358	<p>Harnessing mobile health technology in HIV research: a pilot study utilizing a smartphone-based daily-diary app to collect event-level sexual activity data</p> <p><i>S. Vallabhaneni, W. Hartogensis, N. Sheon, L. Loeb, J. Custer, C. Pilcher, F. Hecht</i> United States</p>
TUPE349	<p>Risk factors associated with HIV infection among female sex workers in the three main urban areas of Mozambique, 2011-2012: results from an RDS survey</p> <p><i>Â.R. Augusto, P. Young, K. Ngale, C. Inguane, I. Sathane, R. Horth, W. McFarland</i> Mozambique</p>	TUPE359	<p>Improving the validity of the measurement of self-reported sexual concurrency in South Africa</p> <p><i>C.E. Zelaya, M.I. Silver, V.F. Go, G. Robertson, W. Davis, G. Gray, D.D. Celentano</i> United States</p>
TUPE350	<p>HIV prevalence and risk factors among Mozambican mineworkers working in South Africa, 2012</p> <p><i>C.S. Baltazar, P. Young, C. Inguane, F. César, R. Horth, H.F. Raymond</i> Mozambique</p>	<hr/>	
TUPE351	<p>Cape Town men who have sex with men (MSM) HIV surveillance probe: are our efforts making a difference for township-based MSM in South Africa?</p> <p><i>B. Brown, A. Scheibe, E. Batist, V. McMahan, R. Grant, L.-G. Bekker</i> South Africa</p>	PE360-369	Reducing risk in adolescents
TUPE352	<p>HIV prevalence and prevention behaviour among long distance truck drivers passing through Inchope, Mozambique in 2012</p> <p><i>H. Frank, C. Botao, P. Young, B. Cummings, C. Inguane, I. Sathane, R. Horth, K. Ngale, W. McFarland, H.F. Raymond</i> Mozambique</p>	TUPE360	<p>Stigma and discrimination as mediators in youth perceptions of HIV risk and prevention: implications for prevention strategies</p> <p><i>M. Raguz</i> Peru</p>
PE353	Assessment of population viral load in epidemiology studies	TUPE361	<p>Risk behaviours among young MSM in Bangkok: a qualitative study to understand and contextualize the high HIV incidence</p> <p><i>T. Chemnasiri, A. Varangrat, S. Chaikummao, S. Hengprasert, K. Pancharoen, P. Luechai, A. Sriporn, K. Satumay, S. Lertpruek, R. Wongbenchaporn, A. Chitwarakorn, T.H. Holtz</i> Thailand</p>
TUPE353	<p>Parallel change of viral load at population level and reported number of new HIV diagnoses in Hong Kong</p> <p><i>N.S. Wong, S.S. Lee, K.H. Wong, K.C.W. Chan</i> China</p>	TUPE362	<p>Sexual practices and HIV-related risk behaviours among secondary school students in Kampala, Uganda</p> <p><i>M. Swaminathan, J. Ssenkusu, D. Serwadda, R. Kwezi, A. Opio, W. Hladik</i> United States</p>
PE354-355	Modelling the epidemiological impact of large scale prevention programs: approaches and results	TUPE363	<p>Teacher preparedness in HIV/AIDS education in multicultural schools of Kakuma Refugee Camp, Kenya</p> <p><i>R. Mandela Ochieng</i> Kenya</p>
TUPE354	<p>The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission</p> <p><i>M. Kato, R. Granich, D. Bui Duc, H. Tran Vu, P. Nadol, D. Jacka, K. Sabin, A. Suthar, F. Mesquita, Y.-R. Lo, B. Williams</i> Vietnam</p>	TUPE364	<p>United for a cause: collaboration between health facility and community-based organizations (CBOs) improve the uptake of HIV among the young people</p> <p><i>R. Ayebare</i> Uganda</p>
TUPE355	<p>The current state of China's expanding and heterogeneous HIV epidemic</p> <p><i>L. Zhang, E. Chow, J. Jing, X. Zhuang, Z. Wu, D. Wilson</i> Australia</p>	TUPE365	<p>Sexual behaviours and condom use among younger versus older college students in North Carolina, U.S.</p> <p><i>R. Safeek, M. McKellar</i> United States</p>
PE356-359	Innovations in the measurement of sensitive behaviours and adherence	TUPE366	<p>I need more miracles in my life: piloting the use of body mapping as a research tool with HIV vulnerable adolescents living in Soweto, South Africa</p> <p><i>P. Smith, J. Dietrich, B. Nklala, C. Tshabalala, G. Gray, C.L. Miller</i> Canada</p>
TUPE356	<p>Evaluating audio computer assisted self-interviews in urban South African communities: evidence for good suitability and reduced social desirability bias of a cross-sectional survey on sexual behaviour</p> <p><i>R. Beauclair, F. Meng, N. Deprez, M. Temmerman, A. Welte, N. Hens, W. Delva</i> South Africa</p>	TUPE367	<p>Factors related to sexual self-efficacy among Thai youth living with HIV/AIDS</p> <p><i>N. Viseskul, W. Fongkaew, S. Settheekul, R.M. Grimes</i> United States</p>
TUPE357	<p>Innovations for respondent-driven sampling: balancing theory and practice to overcome recruitment challenges</p> <p><i>H.-H.M. Truong, M. Grasso, Y.-H. Chen, T. Kellogg, T. Robertson, A. Curotto, W.T. Steward, W. McFarland</i> United States</p>	TUPE368	<p>Benefits of a structured HIV prevention program in reducing the risk of HIV infection among orphans and vulnerable children (OVCs) at Ilinge location in Eastern Cape province (EC), South Africa</p> <p><i>D. Mashelle, J. Jebio Ongole, K. Achebe, G. Jagwer</i> South Africa</p>

TUPE369	<p>Development of a sensation seeking scale for use among vulnerable drug-using populations</p> <p><i>D. Werb, C. Richardson, E. Wood, T. Kerr</i> Canada</p>	TUPE380	<p>The MSM network on twitter in Japan: how high-risk MSM and low-risk MSM exist on the same world</p> <p><i>J. Yanagi</i> Japan</p>
PE370-375	<p>Strategies for identifying most at risk populations (MARPs)</p>	TUPE381	<p>Circular migrations and HIV transmission: a comparison of compartmental and network modeling</p> <p><i>A. Khanna, D. Dimitrov, S. Goodreau</i> United States</p>
TUPE370	<p>Estimating the population size of female sex workers in the three main urban areas of Mozambique, 2011-2012</p> <p><i>C. Inguane, P. Young, H. Frank, R. Horth, K. Ngale, I. Sathane, M. Benedetti, B. Cummings, W. McFarland, H.F. Raymond</i> Mozambique</p>	TUPE382	<p>Sauna affiliation networks of men having sex with men in Hong Kong</p> <p><i>C.M. Poon, S.S. Lee</i> China</p>
TUPE371	<p>Mapping HIV clustering: a strategy for identifying populations at high-risk of HIV infection in Sub-Saharan Africa</p> <p><i>D. Cuadros, L. Abu-Raddad</i> Qatar</p>	PE383-386	<p>Integrating social science research into clinical and biomedical intervention trial</p>
TUPE372	<p>FEM-PrEP strategic recruitment approach to identify and recruit women at higher risk of HIV</p> <p><i>C. Parker, K. Agot, J. Odhiambo, J. Asewe, K. Ahmed, J. Skhosana, M. Ratthagana, M. Lanham, C. Wong, J. Deese, H. Kiernan, S. Mullins, Z. Omungo, S. Chetty-Tulsee, S. Makatu, R. Manongi, I. Reblin, L. Van Damme, A. Corneli</i> South Africa</p>	TUPE383	<p>Effect of antiretroviral therapy on high-risk sexual behaviour</p> <p><i>W. Samaneka, T. Chipato, J. Hakim, G. Mandozana</i> Zimbabwe</p>
TUPE373	<p>A mixed method approach to identifying the characteristics and HIV prevention needs of men who have sex with men (MSM) at highest risk of HIV transmission in a concentrated epidemic</p> <p><i>R. McAdams, L. Carroll, D. Clutterbuck, N. Coia, D. Milne, C. Morrison, J. Shanley, A. Winter</i> United Kingdom</p>	TUPE384	<p>Barriers and facilitators of retention in HIV care and treatment services in Iringa, Tanzania</p> <p><i>C. Tomori, C. Kennedy, H. Brahmabhatt, J. Wagman, J. Mbwambo, S. Likindikoki, D. Kerrigan</i> United States</p>
TUPE374	<p>HIV prevalence and population size estimation among men who have sex with men in three cities in Mozambique, 2011</p> <p><i>R. Nala, T. Lane, C. Inguane, R. Horth, P. Young, W. McFarland</i> Mozambique</p>	TUPE385	<p>Behavioural and social risk characteristics of the FEM-PrEP study population</p> <p><i>J. Headley, A. Lemons, A. Corneli, K. Agot, K. Ahmed, M. Wang, J. Odhiambo, S. Makatu, J. Skhosana, S. Kapiga, R. Manongi, J. Lombaard, L. Van Damme, C. Wong, K. MacQueen, for the FEM-PrEP Study Group</i> Singapore</p>
TUPE375	<p>Assessment of sexual behaviour and self reported importance of and confidence in reducing sexual risk in younger MSM using a local HIV risk assessment tool (HIVRAT)</p> <p><i>J. Alagaratnam, A. Black, A. Smith, O. Dosekun</i> United Kingdom</p>	TUPE386	<p>Risk perception and HIV worry among seroconverters in the FEM-PrEP clinical trial</p> <p><i>K. McKenna, J. Headley, K. Ahmed, K. Agot, S. Makatu, J. Odhiambo, J. Skhosana, M. Stalker, A. Corneli, for the FEM-PrEP Study Group</i> United States</p>
PE376-377	<p>Discordant couples studies</p>	PE387-388	<p>Ethical issues in biomedical prevention, including standard of care</p>
TUPE376	<p>Sources of HIV incidence within stable sexual couples in Sub-Saharan Africa</p> <p><i>H. Chemaitelly, L. Abu-Raddad</i> Qatar</p>	TUPE387	<p>Positive social impacts related to participation in a multinational HIV prevention trial involving medication assisted treatment of people who inject drugs</p> <p><i>J. Sugarman, K. Bokoch, R. Stalter, HPTN 058 Study Team</i> United States</p>
TUPE377	<p>Barriers to antiretroviral therapy initiation for HIV serodiscordant couples: an observational study in 40 counties, China</p> <p><i>J. Li, Y. Mao, H. Tang, J. Han, D. Sun, W. Lai, M. Ni, M. Jia, W. Liu</i> China</p>	TUPE388	<p>South African stakeholder perspectives regarding ethical guidance on prevention and care in HIV vaccine trials</p> <p><i>R. Moorhouse, C. Slack, Z. Essack, M. Quayle, G. Lindegger</i> Canada</p>
PE379-382	<p>Network studies of risk behaviours and their implications for prevention</p>	PE389-392	<p>Community involvement in biomedical prevention</p>
TUPE379	<p>Piloting contingency management intervention among needle exchange program users in Tirana, Albania</p> <p><i>A. Boci, A. Zazo, E. Hallkaj</i> Albania</p>	TUPE389	<p>Experiences of assessing retention rates using mobile phones versus physical contact tracing in a potential HIV vaccine efficacy population cohort of fishing communities along Lake Victoria, Uganda</p> <p><i>A.N. Kivumbi, J. Mpendo, A. Nanvubya, A. Ssetaala, S. Sigirenda, M. Wambuzi, N. Kiwanuka</i> Uganda</p>

TUPE390	<p>A survey of community opinions and preferences on PrEP, microbicides and vaccines in 5 regions and with key populations in Kenya</p> <p><i>B.P. Ngongo, J. Mbogua, B. Bender, F. Manguyu, J. Ndegwa</i> Kenya</p>	TUPE399	<p>Reducing 30-day hospital readmissions among people living with HIV/AIDS using the lean process improvement methodology</p> <p><i>R. Smith</i> United States</p>
TUPE391	<p>Evaluation of stakeholder advisory mechanisms in HIV prevention research trials</p> <p><i>J. Mbogua, P. Bahati, B. Bender</i> Kenya</p>	TUPE400	<p>Hopefulness fosters positive affects and actions for coping, adherence and quality of life among people living with HIV/AIDS in Dar es Salaam, Tanzania</p> <p><i>H. Neema Siril, M. Watty, N. Ware, M.C.S. Fawzi, J. Kilewo, J. Todd, S. Kaaya</i> Tanzania, United Republic of</p>
TUPE392	<p>Intimate partner violence among people living with HIV attending a treatment clinic in LAUTECH Teaching Hospital in Osogbo, Nigeria</p> <p><i>A. Adejimi, K. Adebayo, C. Akinleye</i> Nigeria</p>	TUPE401	<p>Mobile phone texting may be a viable tool for improving ART adherence amongst patients receiving HIV care in rural Uganda</p> <p><i>L. Lourenco, J.E. Min, M. Nyonyitono, S. Shurgold, J. Birungi, R. Makabayi-Mugabe, J. Wangisi, J. Montaner, D. Moore</i> Canada</p>
Track D >	Operations and Implementation Research	TUPE402	<p>Increasing health system efficiency: use of motorcycles for patient outreach in Kisumu, Nyanza province</p> <p><i>D. O'Farrell, K. Nichols, K. Harrison, M. Lutukai, J. Lewis-Kulzer, G. Agengo, P. Oyaro, I. Sakura</i> United Kingdom</p>
PE393-398	Methods to increase demand for services for prevention and care (e.g. incentives, peer promotion, phone-base communication)	TUPE403	<p>Delivery of methadone treatment in Dar es Salaam, Tanzania: dose, age and history of abuse impact clients' risk of defaulting from treatment</p> <p><i>B. Lambdin, D. Bruce, O. Chang, F. Masao, C. Nyandindi, Y. Ivo, A. Msami, N. Sabuni, E. Matiko, K. Kazaura, S. McCurdy, J. Mbwambo</i> United States</p>
TUPE393	<p>A programme to educate expert mothers in promoting HIV and preventive health interventions for children at community-level in the Lake and Southern Highlands zones of Tanzania</p> <p><i>M. Mjnde, B. Anosike, L. Campbell, T. Vu, E. Kanga, S. Manumbu, E. Opere, N. Mataluma, E. Batungi, S. Shea, V. Mng'ong'o, A. Bisetsa, R. Msaki, F. Mkinga, G. Wilson, S. Kisyombe, J. Bradford, J. Bacha, L. Tolle, F. Myinga, S. Shabushi, A. Mwale, L. Mwita, M. Tolle</i> Tanzania, United Republic of</p>	TUPE404	<p>Correlates of patient retention in HIV care and treatment programs in Nigeria</p> <p><i>C.C. Ugoji, R. Ake-Uzoigwe, M.Y. Ladele, C. Akolo, G. Mendy, P. Dakum, M. Charurat, H. Isah, D. Onotu, O. Nwanyanwu, W. Blattner</i> Nigeria</p>
TUPE394	<p>Health extension workers and locally comprehensible materials attracting more men to circumcision services in Gambella, Ethiopia</p> <p><i>T. Bogale, A. Shume, E. Daniel, J. Bol, K. Curran, T. Adamu</i> Ethiopia</p>	PE405-412	Strategies to increase linkage to HIV care among those in need
TUPE395	<p>Sexual pleasure, reduced STIs and peer norms: underlying motivations for seeking voluntary medical male circumcision (VMMC) in Gauteng, South Africa</p> <p><i>S. Nieuwoudt, S. Frade, A. Spyrelis, D. Taljaard, D. Rech</i> South Africa</p>	TUPE405	<p>The PeerCARE study, a randomized, controlled trial of the impact of peers on linkage to care, preventive care and sexual behaviours among PLHIV not on antiretroviral therapy: baseline findings</p> <p><i>L. Chang, G. Nakigozi, J. Mulamba, D. Migadde, D. Serwadda, M. Hosein, M. Wawer, R. Bollinger, T. Quinn, R. Gray, G. Kigozi, S. Reynolds</i> Uganda</p>
TUPE396	<p>Scaling up HIV/AIDS services in hard-to-reach areas in Uganda</p> <p><i>J. Kayizzi Barnes</i> Uganda</p>	TUPE406	<p>Routine outreach services improve access to HIV care and treatment services among remote and mobile fishing communities on the islands of Lake Victoria</p> <p><i>J. Zelothe, B. S'ongora, D. Simbeye, G. Antelman, L. Mukimara, M. Mfaume, D. Masaliwa, A. Almeida, H. Nuwagaba-Biribonwoha, A. Zewde</i> Tanzania, United Republic of</p>
TUPE397	<p>Implementing a peer facilitator program to increase uptake of PMTCT services in Hurungwe district, Zimbabwe</p> <p><i>C. Mukandi</i> Zimbabwe</p>	TUPE407	<p>Intra-facility linkage of HIV-positive mothers and exposed infants into HIV chronic care: rural and urban experiences in a resource-limited setting</p> <p><i>C. Mugasha, J. Kigozi, A. Muganzi, A. Kiraga, N. Sewankambo, A. Coutinho, D. Nakanjako</i> Uganda</p>
TUPE398	<p>The effect of a formal invitation letter and community sensitisation on increasing male participation in the PMTCT programme in Chitungwiza, 2012</p> <p><i>V. Makani, W. Chandisarewa, A. Mushavi, B. Makunike-Chikwinya, S. Rusakaniko</i> Zimbabwe</p>	TUPE408	<p>Increasing availability and access to HIV treatment in Nyanza province, Kenya</p> <p><i>D.M. Paulo, L. Matu, C. Okal, D. Omondi, B. Ochuka, J. Kose, J. Ongetch, T. Syengo, J. Kioko</i> Kenya</p>
PE399-404	Interventions to improve long-term adherence to treatment and biomedical prevention		

TUPE409	<p>Towards a male-centered model of care: understanding male preferences and barriers to HIV care in Khayelitsha, South Africa</p> <p><i>V. Cox, A. Campbell, N. Raphahlelo, J. McIntyre, K. Rebe</i> South Africa</p>	TUPE419	<p>Community experiences and perspectives on the initiation of lifelong ART in pregnant women ('Option B+'): a multi-country consultation to inform the WHO 2013 consolidated ARV guidelines</p> <p><i>A. Hsieh, S. Haerizadeh, L. Mworeko, J. Kamwana, A. Garner, M. Ram, N. Keeble, A. Baller, N. Shaffer</i> Netherlands</p>
TUPE410	<p>Door-to-door voluntary HIV test and TB screening: an experience in rural Mozambique</p> <p><i>S. Pestilli, J. Llenas-Garcia, P. Wikman, A.M. Mussa, F. Mbofana, E. Larsson, J. Ehmer, M. Hobbins</i> Mozambique</p>	TUPE420	<p>Barriers to antiretroviral therapy (ART) initiation for treatment-eligible HIV-positive pregnant women in Swaziland</p> <p><i>K. Kudjabor, L. Katirayi, C. Chouraya, B. Nhlabatsi, M. Mahdi</i> Swaziland</p>
TUPE411	<p>Client experiences and perspectives on the linkage to care following home-based HIV counseling and testing: a qualitative study in rural South Africa</p> <p><i>R. Naik, T. Doherty, D. Jackson, W. Zembe, F. Feeley</i> South Africa</p>	PE421-429	<p>Interventions to improve retention in the PMTCT cascade, including early infant diagnosis</p>
TUPE412	<p>Active case finding: a comparison of home-based testing and health center-based testing for identifying HIV-infected children in Lilongwe, Malawi</p> <p><i>S. Ahmed, M.H. Kim, A.C. Dave, K. Kanjelo, N. Kim El-Mallawany, P.N. Kazembe</i> Malawi</p>	TUPE421	<p>Coming of age: HIV exposed infants (HEI) graduation ceremonies at 18 months, the Sauri Millennium Villages cluster experience, Kenya</p> <p><i>M. Adudans, J. Wariero, S. Komollo, J. Masira, Y. Ben Amor</i> Kenya</p>
PE413-417	<p>Operational challenges in implementing test and treat strategy</p>	TUPE422	<p>Elimination of mother to child HIV transmission in Thai Nguyen, Vietnam: it is achievable</p> <p><i>V.T.T. Nguyen, K.A. Le Ai, K. Sabin, Q.T. Ho, M. Kato, F. Mesquita, C. Hayashi</i> Vietnam</p>
TUPE413	<p>Anti-Homosexuality Bill (AHB), 2012 and anti-HIV strategic planning targeting sexual minorities in Uganda: analysing 'health' and access from 2009-2012</p> <p><i>T.R. Muyunqa-Mukasa, N. Ssemujju</i> United States</p>	TUPE423	<p>Retention of Pre-ART clients in care: impact of stage specific interventions</p> <p><i>C. Nwuba, I. Livinus, M. Okoye, N. Nwokedi, O. Giwa, A. Omolajo</i> Nigeria</p>
TUPE414	<p>Operational challenges to implementing test and treat: thinking about systems at the primary services level</p> <p><i>S.M. Topp</i> Zambia</p>	TUPE424	<p>Feasibility of population-based cross-sectional surveys for estimating vertical HIV transmission: data from Zimbabwe</p> <p><i>R. Buzdugan, S.I. McCoy, M. Petersen, L.A. Guay, A. Mushavi, A. Mahomva, A. Hakobyan, F.M. Cowan, N.S. Padian</i> United States</p>
TUPE415	<p>Pre-ART patient loss to care (PALC) in primary care facilities using nurse initiated management of ART (NIMART) in Tshwane district, South Africa: a retrospective cohort study</p> <p><i>M.I. Vincenz, F. Senkubuge, H.-F. Kinkel</i> South Africa</p>	TUPE425	<p>Uptake of prevention of mother to child HIV transmission (PMTCT) services among women with a recent birth in Zimbabwe</p> <p><i>S.I. McCoy, R. Buzdugan, T.E. Martz, A. Mushavi, A. Mahomva, N.S. Padian, F.M. Cowan</i> United States</p>
TUPE416	<p>Community perspectives on when to initiate ART and the use of ARVs for prevention: a multi-country e-consultation to inform the WHO 2013 consolidated ARV guidelines</p> <p><i>A.K. Teltschik, A. Garner, M. Ram, C. Mallouris, A. Hsieh, C. Irvine, P. Easterbrook, M.A. De Avila, M. Doherty, A. Ball</i> United States</p>	TUPE426	<p>Effective strategies to improve uptake of essential services and retention through the PMTCT cascade: a case of 'active client follow-up' in east central Uganda</p> <p><i>S. Auma, E. Skowronska, B. Mugisha, M. Mbule, F. Kazibwe, M. Besser, A. Myers, E. Okonji, K. Schmitz</i> South Africa</p>
TUPE417	<p>Argentinean HIV care providers' attitudes and practices towards HAART initiation at higher CD4 counts</p> <p><i>M.E. Socías, O. Sued, D. Pryluka, M.I. Figueroa, P. Patterson, P. Cahn</i> Argentina</p>	TUPE429	<p>Poor postpartum retention in HIV care in an urban U.S. setting</p> <p><i>D.V. McGregor, R. Bhatia, S. Sutton, S. Reddy, B. Taiwo</i> United States</p>
PE418	<p>Feasibility of treatment as prevention in various socio-economic setting and key populations (MSM, FSWs, PWID, etc.)</p>	PE430-434	<p>Strategies to improve outcomes in HIV-infected children (e.g. nutritional and other kinds of social support, child counselling services, disclosure and measures to improve adherence)</p>
TUPE418	<p>Willingness of Argentinean HIV care providers to adopt PrEP as a risk reduction strategy in different scenarios</p> <p><i>M.E. Socías, O. Sued, D. Pryluka, V. Fink, C. Cesar, P. Cahn</i> Argentina</p>		
PE419-420	<p>Operational challenges and feasibility of PMTCT option B+ in various contexts</p>		

TUPE430 **Paediatric antiretroviral treatment (ART):
health care worker perspectives
contributing to the WHO 2013
consolidated guidelines development**

*M. Penazzato, L.J. Nelson, J. Ellis, S. Essajee,
A. Nardone, A. Baller, N. Shaffer, M. Doherty,
L.M. Muhe
Switzerland*

TUPE431 **Implementing 2013 WHO guidelines for
children: ensuring scale up of effective
interventions**

*L.J. Nelson, M. Penazzato, L. Muhe, N. Shaffer,
M. Vitoria, V. Habiyambere, J. Perriens, M.
Beusenbergh, M. Doherty
Switzerland*

TUPE432 **HIV disclosure and clinical outcomes
among HIV-infected adolescents enrolled
in HIV care in Kenya 2004-2011: results
from a national retrospective cohort study**

*E. Nguji, B. Ngeno, A. Katana, L. Nganga, A.
Waruru, A. Gichangi, I. Mukui, J. Wamicwe, I.
Inwani
Kenya*

TUPE433 **HIV disclosure: the situation of
adolescents born with HIV in Thailand**

*S. Le Coeur, E. Lelièvre, C. Kanabkaew, P.
Techakunakorn, C. Ngampiyaskul, V.
Wanchaitanawong, S. Buranabanasatean, W.
Karnchanamayul, J. Nitipipatkosol, B. Warachit,
N. Akarathum, TEEWA Study Group
France*

TUPE434 **Paediatric palliative care needs and best
practices in Sub-Saharan Africa:
perspectives from frontline HIV
healthcare workers**

*H.S. Soeters, S. Essajee, L. Sherr, S. Rollnick,
J. Altschuler, J. Marston, A. Kiboneka, M.
Evans, R. Norman, C. Penn, J. Nuttall, E.
Obimbo, S. Stulac, P. Onguti, D. Mark
South Africa*